Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations
Background: The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1mut-neg/CEBPAdm-neg/FLT3-ITD...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
01 September 2017
|
| In: |
Annals of oncology
Year: 2017, Jahrgang: 28, Heft: 11, Pages: 2793-2798 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdx500 |
| Online-Zugang: | Verlag, kostenfrei registrierungspflichtig, Volltext: http://dx.doi.org/10.1093/annonc/mdx500 Verlag, kostenfrei registrierungspflichtig, Volltext: https://academic.oup.com/annonc/article/28/11/2793/4101658 
|
| Verfasserangaben: | K. Heidrich, C. Thiede, K. Schäfer-Eckart, N. Schmitz, W.E. Aulitzky, A. Krämer, W. Rösler, M. Hänel, H. Einsele, C.D. Baldus, R.U. Trappe, F. Stölzel, J.M. Middeke, C. Röllig, F. Taube, M. Kramer, H. Serve, W.E. Berdel, G. Ehninger, M. Bornhäuser, J. Schetelig |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571947701 | ||
| 003 | DE-627 | ||
| 005 | 20220814112401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180412s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdx500 |2 doi | |
| 035 | |a (DE-627)1571947701 | ||
| 035 | |a (DE-576)501947701 | ||
| 035 | |a (DE-599)BSZ501947701 | ||
| 035 | |a (OCoLC)1341002149 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Heidrich, Katharina |d 1987- |e VerfasserIn |0 (DE-588)115594416X |0 (DE-627)1018500049 |0 (DE-576)501947191 |4 aut | |
| 245 | 1 | 0 | |a Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations |c K. Heidrich, C. Thiede, K. Schäfer-Eckart, N. Schmitz, W.E. Aulitzky, A. Krämer, W. Rösler, M. Hänel, H. Einsele, C.D. Baldus, R.U. Trappe, F. Stölzel, J.M. Middeke, C. Röllig, F. Taube, M. Kramer, H. Serve, W.E. Berdel, G. Ehninger, M. Bornhäuser, J. Schetelig |
| 264 | 1 | |c 01 September 2017 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.04.2018 | ||
| 520 | |a Background: The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML) in first complete remission (CR1). Patients and methods: We addressed this question using data from two prospective randomized controlled trials on intensive induction- and risk-stratified postremission therapy. The NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML subgroup comprised 497 patients, aged 18-60 years. Results: In donor versus no-donor analyses, patients with a matched related donor had a longer relapse-free survival (HR 0.5; 95% CI 0.3-0.9, P = 0.02) and a trend toward better overall survival (HR 0.6, 95% CI 0.3-1.1, P = 0.08) compared with patients who received postremission chemotherapy. Notably, only 58% of patients in the donor group were transplanted in CR1. We therefore complemented the donor versus no-donor analysis with multivariable Cox regression analyses, where alloHCT was tested as a time-dependent covariate: overall survival (HR 0.58, 95% CI 0.37-0.9, P = 0.02) and relapse-free survival (HR 0.51, 95% CI 0.34-0.76; P = 0.001) for patients who received alloHCT compared with chemotherapy in CR1 were significantly longer. Conclusion: Outside clinical trials, alloHCT should be the preferred postremission treatment of patients with intermediate risk NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML in CR1.Cinicaltrials.gov identifierNCT00180115, NCT00180102 | ||
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 28(2017), 11, Seite 2793-2798 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g number:11 |g pages:2793-2798 |g extent:6 |a Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdx500 |x Verlag |z kostenfrei registrierungspflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/28/11/2793/4101658 |x Verlag |z kostenfrei registrierungspflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180412 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1571947701 |e 3005940462 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Heidrich","roleDisplay":"VerfasserIn","given":"Katharina","display":"Heidrich, Katharina","role":"aut"},{"given":"Alwin","display":"Krämer, Alwin","role":"aut","roleDisplay":"VerfasserIn","family":"Krämer"}],"physDesc":[{"extent":"6 S."}],"name":{"displayForm":["K. Heidrich, C. Thiede, K. Schäfer-Eckart, N. Schmitz, W.E. Aulitzky, A. Krämer, W. Rösler, M. Hänel, H. Einsele, C.D. Baldus, R.U. Trappe, F. Stölzel, J.M. Middeke, C. Röllig, F. Taube, M. Kramer, H. Serve, W.E. Berdel, G. Ehninger, M. Bornhäuser, J. Schetelig"]},"relHost":[{"title":[{"title":"Annals of oncology","title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"id":{"issn":["1569-8041"],"zdb":["2003498-2"],"eki":["320428796"]},"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"disp":"Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutationsAnnals of oncology","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"part":{"text":"28(2017), 11, Seite 2793-2798","issue":"11","volume":"28","year":"2017","extent":"6","pages":"2793-2798"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796","pubHistory":["1.1990 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology","role":"isb"}]}],"language":["eng"],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"01 September 2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1571947701"],"doi":["10.1093/annonc/mdx500"]},"title":[{"title":"Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations","title_sort":"Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations"}],"recId":"1571947701","note":["Gesehen am 12.04.2018"]} | ||
| SRT | |a HEIDRICHKAALLOGENEIC0120 | ||